Normunity de-stealths, launches Series A immune normalisers
pharmaphorum
OCTOBER 26, 2022
has exited stealth with a $65 million Series A to create a new class of medicines that target novel I-O mechanisms, which free the body’s normal immunity against cancer. Called “immune normalisers”, these targets are drawn from an ongoing and interactive academic-biotech research alliance within the Yale School of Medicine.
Let's personalize your content